BRIEF published on 01/19/2026 at 07:35, 1 month 28 days ago FDA Reviews Advicenne's Sibnayal® for U.S. Approval FDA Advicenne Sibnayal® DRTA PDUFA Date
BRIEF published on 01/19/2026 at 07:35, 1 month 28 days ago Advicenne: FDA-approved marketing application for Sibnayal® FDA ATRd Advicenna Sibnayal® PDUFA
PRESS RELEASE published on 01/19/2026 at 07:30, 1 month 28 days ago Inside Information / Other news releases FDA accepts Advicenne's Marketing Authorization Application for Sibnayal® for dRTA treatment in the US, with a PDUFA decision target date of September 3rd, 2026 FDA Advicenne Sibnayal DRTA PDUFA
BRIEF published on 01/12/2026 at 07:35, 2 months 4 days ago Renewal of the marketing authorization for Sibnayal® in the European Union Kidney Disease EMA Advicenna AMM Sibnayal®
BRIEF published on 11/04/2025 at 11:35, 4 months 12 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 4 months 12 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 5 months 27 days ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 7 months 19 days ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 7 months 19 days ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 7 months 22 days ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
Published on 03/16/2026 at 22:30, 2 hours 20 minutes ago Core Silver Intersects High-Grade Copper-Molybdenum Veins up to 7.31% Cu & 1.01% Mo Confirming Large Porphyry System at Laverdiere
Published on 03/16/2026 at 22:00, 2 hours 50 minutes ago Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Published on 03/16/2026 at 21:30, 3 hours 20 minutes ago Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Published on 03/16/2026 at 21:00, 3 hours 50 minutes ago Amdocs Brings AI-Accelerated Application Modernization to Enterprises with NVIDIA
Published on 03/17/2026 at 00:00, 49 minutes ago Cango Inc. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
Published on 03/16/2026 at 23:07, 1 hour 42 minutes ago KION brings physical AI into live warehouse operations at GTC 2026 in San José, California
Published on 03/16/2026 at 22:35, 2 hours 14 minutes ago Nscale and Microsoft Announce Collaboration with NVIDIA and Caterpillar to Deliver 1.35GW of NVIDIA Vera Rubin NVL72 GPUs at Flagship AI Factory Campus in West Virginia
Published on 03/16/2026 at 22:25, 2 hours 24 minutes ago Nscale Acquires American Intelligence & Power Corporation, Creating a Full Stack AI Hyperscaler, Integrated from Energy to Compute
Published on 03/16/2026 at 21:35, 3 hours 14 minutes ago WEKA Maximizes Token Output With Lower Cost Per Token on NVIDIA BlueField-4 STX
Published on 03/16/2026 at 18:00, 6 hours 50 minutes ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 6 hours 52 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 6 hours 53 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:35, 7 hours 15 minutes ago Disclosure of transactions in own shares from March 9 to March 13, 2026
